sci天天读
80mg奥希替尼治疗EGFR突变阳性相关脑膜转移的非小细胞肺癌患者的II期临床试验的疗效和安全性
SCI19 June 2024Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)
2023 年美国胸外科协会 (AATS) 专家共识文件： 亚实性肺结节的管理
SCI18 June 2024The 2023 American Association for Thoracic Surgery (AATS) Expert Consensus Document: Management of subsolid lung nodules
哌甲酯与安慰剂在治疗晚期癌症患者疲劳中的对比研究：随机、双盲、多中心、安慰剂对照试验
SCI17 June 2024Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial
评估癌症治疗分散化对环境和下游人类健康的影响
SCI16 June 2024Assessing the Environmental and Downstream Human Health Impacts of Decentralizing Cancer Care
SURMOUNT-CN试验：中国肥胖成年人Tirzepatide的减肥作用
SCI15 June 2024Tirzepatide for Weight Reduction in Chinese Adults With Obesity-The SURMOUNT-CN Randomized Clinical Trial
临床验证：游离细胞DNA片段组测定增强肺癌早期检测
SCI14 June 2024Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection
洛拉替尼与克唑替尼在ALK阳性晚期非小细胞肺癌患者中的应用：III期CROWN研究的5年结果
SCI13 June 2024Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Garsorasib治疗中国KRASG¹²C突变非小细胞肺癌患者:一项开放标签、多中心、单组、2期试验
SCI12 June 2024Garsorasib in patients with KRASG¹²C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial
机器人肺切除术后带胸腔引流管及数字引流系统出院
SCI11 June 2024Discharging Patients Home with a Chest Tube and Digital System after Robotic Lung Resection
0610 晚期实体瘤患者的全身抗癌治疗及总生存率
SCI10 June 2024Systemic Anticancer Therapy and Overall Survival in Patients with Very Advanced Solid Tumors
Pamrevlumab治疗特发性肺纤维化：ZEPHYRUS-1随机临床试验
SCI9 June 2024Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial
立体定向体部放疗治疗中央型无法手术的早期NSCLC：EORTC 22113-08113 LungTech II期试验结果
SCI8 June 2024Stereotactic body radiotherapy for centrally located inoperable early-stage NSCLC: EORTC 22113-08113 LungTech phase II trial results
在肿瘤抑制的新时代理解p53的复杂性
SCI7 June 2024Understanding the complexity of p53 in a new era of tumor suppression
全面的外周血免疫谱分析揭示了癌症患者具有五种免疫治疗反应特征的免疫类型
SCI6 June 2024Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer
癌症研究人员人工智能指南
SCI5 June 2024A guide to artificial intelligence for cancer researchers
III期EGFR突变NSCLC放化疗后应用奥希替尼
SCI4 June 2024Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
电子鼻技术诊断I期癌症的真实世界评估
SCI3 June 2024A real-world assessment of stage I lung cancer through electronic nose technology
应用免疫疗法晚期非小细胞肺癌患者的身体成分
SCI2 June 2024Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy
早期诊断和治疗慢性阻塞性肺疾病（COPD）和哮喘的随机对照试验
SCI1June 2024Early Diagnosis and Treatment of COPD and Asthma — A Randomized, Controlled Trial
致癌信号的治疗性过度激活作为癌症潜在治疗策略的案例
SCI1 May 2024The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy